This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Pradaxa®, an anti-clotting medication approved to prevent the formation of blood clots in patients with atrial fibrillation not caused by cardiac valve deficiencies. Atrial fibrillation, or A-Fib, as it is commonly known, occurs when the atrial chambers of the heart (the smaller, upper chambers) beat in an irregular fashion so that they are rhythmically out of sync with the lower, larger chambers of the heart – the ventricles. A-Fib can be caused by numerous conditions. Pradaxa® has also been approved to prevent the development of blood clots, deep vein thrombosis (DVT) and pulmonary embolisms (PE) in patients who have undergone hip replacement surgery and to reduce the risk of recurrence of DVT and PE in patients who were previously treated.
Since it first entered the market, Pradaxa® has been associated with serious bleeding injuries including gastro-intestinal bleeds, hemorrhagic stroke (brain bleeds) and uncontrollable bleeding resulting from traumatic injuries (car accidents, falls, etc.). Until the end of 2015, doctors had no way of controlling life-threatening bleeds caused by Pradaxa®.
In the fall of 2015, the FDA approved Praxbind® (idarucizumab, the Pradaxa® "reversal agent" manufactured and sold by Boehringer Ingelheim the manufacturer of Pradaxa® a full five years after Pradaxa hit the market. One prescribed dose of Praxbind® required to stop uncontrollable bleeding brought on by the use of Pradaxa® will cost the patient $3,500. However, though it can reduce the extent of the damage, this rescue agent does not prevent Pradaxa®-induced serious bleeding injuries from occurring in the first place.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.